Zhigao Li - Publications

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Journal: The New England journal of medicine

Published: December 10, 2025

Immune-metabolic profiling of triple-negative breast cancer during neoadjuvant chemotherapy.

Journal: iScience

Published: November 13, 2025

Endothelial-derived PANoptosis factor IL33 is a potential immunotherapy in breast cancer.

Journal: iScience

Published: October 15, 2025

Transcriptome-wide analysis reveals potential roles of CFD and ANGPTL4 in fibroblasts regulating B cell lineage for extracellular matrix-driven clustering and novel avenues for immunotherapy in breast cancer.

Journal: Molecular medicine (Cambridge, Mass.)

Published: December 02, 2024

Effectiveness of sequential method pure single-port lumpectomy-breast conserving surgery for early-stage breast cancer in different quadrants

Journal: Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery

Published: July 16, 2024

Correction: FN1-mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.

Journal: Breast cancer research and treatment

Published: December 28, 2023

Unveiling heterogeneity and prognostic markers in ductal breast cancer through single-cell RNA-seq.

Journal: Cancer cell international

Published: November 01, 2023

Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.

Journal: Cancer research and treatment

Published: May 11, 2023

Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio.

Journal: Medicina (Kaunas, Lithuania)

Published: May 08, 2023

Cancer stem cells promote lymph nodes metastasis of breast cancer by reprogramming tumor microenvironment.

Journal: Translational oncology

Published: April 28, 2023

FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.

Journal: Breast cancer research and treatment

Published: March 16, 2023

A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.

Journal: Nature communications

Published: July 27, 2022